United States News All stories

Stifel Financial (NYSE:SF) reported third-quarter 2026 net income available to common shareholders of $224.8 million, up 11.3% year over year, despite slightly lower revenue.

CME Group (NASDAQ:CME) reported third-quarter 2026 revenue of $1.74 billion, up 13% year over year from $1.54 billion, exceeding analysts' expectations of $1.71 billion.

Moody’s Corporation (NYSE:MCO) reported third-quarter 2026 revenue of $2.02 billion, up 1% year over year but below analysts’ expectations of $2.08 billion.

Winnebago Industries (NYSE:WGO) reported fiscal fourth-quarter 2026 revenue of $645.1 million, down 17% year over year from $777.3 million, reflecting lower recreational vehicle sales volumes.

Philip Morris International (NYSE:PM) reported third-quarter 2026 revenue of $11.44 billion, up 5.5% year over year, exceeding analysts' estimates amid growth across its tobacco and nicotine businesses.

Northern Trust Corporation (NASDAQ:NTRS) reported third-quarter 2026 revenue of $2.294 billion, up 13.3% year over year, supported by stronger fee and interest income.

Teledyne Technologies (NYSE:TDY) reported record third-quarter 2026 sales of $1.68 billion, up 9.4% year over year, alongside higher operating profit and earnings.

Merck (NYSE:MRK) announced European Commission approval of KEYTRUDA plus Padcev for adults with resectable muscle-invasive bladder cancer, regardless of eligibility for cisplatin-based chemotherapy.

BankUnited (NYSE:BKU) reported third-quarter 2026 net income of $72.2 million, compared with $70.7 million sequentially and $71.9 million a year earlier.

APEX Tech Acquisition (NYSE:TRAD) reportedly agreed to merge with entertainment platform Korai Flix at a pre-money equity valuation of $3.5 billion.

Wabtec Corporation (NYSE:WAB) reported third-quarter 2026 sales of $3.12 billion, up 8.1% year over year, driven by growth across its Freight and Transit businesses.

AT&T (NYSE:T) reported third-quarter 2026 revenue of $32.3 billion, up 5.3% year over year, supported by growth in its advanced connectivity businesses.

Integra LifeSciences (NASDAQ:IART) reported third-quarter 2026 revenue of $411.2 million, up 2.3% year over year despite supply disruptions at its Cincinnati manufacturing facility.

Elevance Health (NYSE:ELV) reported third-quarter 2026 operating revenue of $50.4 billion, up 0.7% year over year, supported by its diversified healthcare businesses.

Thermo Fisher Scientific (NYSE:TMO) reported third-quarter 2026 revenue of $12.14 billion, up 9% year over year, supported by growth across its scientific products and services businesses.

Danaher (NYSE:DHR) reported third-quarter 2026 revenue of $6.554 billion, up 8.5% year over year, supported by growth across its life sciences and diagnostics operations.

SCHMID Group (NASDAQ:SHMD) raised its full-year 2026 order intake guidance to more than €150 million following stronger equipment demand during the third quarter.

NVIDIA (NASDAQ:NVDA) introduced DSX POD, a modular reference design intended to accelerate AI factory deployment by integrating and testing computing infrastructure before delivery.

Lithia & Driveway (NYSE:LAD) reported third-quarter 2026 revenue of $9.95 billion, up 2.8% year over year, while net income increased 34% to $292.9 million.

Oil prices climbed more than $1 on Wednesday as escalating Middle East tensions heightened concerns about supply disruptions, while declining U.S. inventories supported crude futures.

Ascentage Pharma (NASDAQ:AAPG) received Breakthrough Therapy Designation in China for lisaftoclax combined with acalabrutinib as a potential first-line treatment for adults with CLL/SLL.

GSK (NYSE:GSK) received U.S. Food and Drug Administration approval for Hibsago (bepirovirsen), an RNA-targeted treatment for certain adults with chronic hepatitis B.

HUTCHMED (NASDAQ:HCM) finalized its licensing agreement with GSK (NYSE:GSK) for investigational cancer therapy HMPL-A830, following completion of customary closing conditions and antitrust regulatory reviews.

Ionis Pharmaceuticals (NASDAQ:IONS) said partner GSK (NYSE:GSK) received U.S. FDA approval for Hibsago, an RNA-targeted treatment for certain adults with chronic hepatitis B.